TScan Therapeutics, Inc.

TCRX

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001783328

SEC filings (opens in a new tab)

No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding TScan Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024 All holders in Q1 2024

13F holders of TCRX: Q1 2024 compared with Q2 2024
Measure	Q1 2024	Of which not filed for Q2 2024	Q2 2024	Change
Holders	66	1	81	+16
Shares	34.3M	17.4K	41.5M	+7.20M (+21.0%)
Value	$272.3M	$137.9K	$242.6M	−$29.6M (−10.9%)

1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (32)

Institutions that held TScan Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to TCRX in Q2 2024
Institution	Shares	Value	% of portfolio
Great Point Partners LLC	940,831	$5.50M	1.05%
StemPoint Capital LP	845,069	$4.94M	1.45%
LMR Partners LLP	665,529	$3.89M	0.08%
Paradigm Biocapital Advisors LP	353,886	$2.07M	0.08%
Woodline Partners LP	163,492	$956.4K	0.01%
Alpine Global Management, LLC	137,490	$804.3K	0.14%
Bank of Montreal	120,454	$749.2K	0.00%
Bank of New York Mellon Corp	116,658	$682.4K	0.00%
Troluce Capital Advisors LLC	92,832	$543.1K	0.11%
Wellington Management Group LLP	90,941	$532.0K	0.00%
Brown Brothers Harriman & Co	76,024	$444.7K	0.00%
Nuveen Asset Management, LLC	69,962	$409.3K	0.00%
Rhumbline Advisers	46,867	$274.2K	0.00%
Cornercap Investment Counsel Inc	22,940	$134.2K	0.02%
EntryPoint Capital, LLC	21,899	$128.1K	0.06%
Corebridge Financial, Inc.	20,658	$121.1K	0.00%
Deutsche Bank AG	20,638	$120.7K	0.00%
New York State Common Retirement Fund	20,093	$117.5K	0.00%
Squarepoint Ops LLC	19,290	$112.8K	0.00%
Manufacturers Life Insurance Company, The	15,383	$90.0K	0.00%
Voya Investment Management LLC	13,603	$79.6K	0.00%
Barclays PLC	13,164	$77.0K	0.00%
Advisor Group Holdings, Inc.	12,245	$71.6K	0.00%
Dimensional Fund Advisors LP	11,882	$70.5K	0.00%
MetLife Investment Management	10,199	$59.7K	0.00%
Tower Research Capital LLC (TRC)	4,224	$24.7K	0.00%
Legal & General Group Plc	3,937	$23.0K	0.00%
Ameritas Investment Partners, Inc.	3,762	$22.0K	0.00%
Royal Bank of Canada	3,611	$21.0K	0.00%
California State Teachers Retirement System	2,782	$16.3K	0.00%
Amalgamated Bank	1,329	$8.00K	0.00%
Price T Rowe Associates Inc	12,301	$0	0.00%

Sold out (16)

Institutions that held TScan Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of TCRX in Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
Susquehanna International Group, LLP	297,902	$2.37M
Cubist Systematic Strategies, LLC	44,308	$351.8K
Balyasny Asset Management LLC	41,942	$333.0K
Two Sigma Investments, LP	37,747	$299.7K
ExodusPoint Capital Management, LP	35,661	$283.0K
HRT Financial LP	34,789	$276.0K
Brevan Howard Capital Management LP	34,578	$274.5K
Y-Intercept (Hong Kong) Ltd	24,446	$194.1K
Point72 Asia (Singapore) Pte. Ltd.	19,736	$156.7K
Cannon Global Investment Management, LLC	17,500	$138.9K
Omers Administration Corp	14,200	$112.7K
Jefferies Financial Group Inc.	12,200	$96.9K
CTC Alternative Strategies, Ltd.	11,000	$87.3K
Cambridge Investment Research Advisors, Inc.	10,061	$80.0K
Federated Hermes, Inc.	56	$445
Macquarie Group Ltd	1,618	$13

Not filed for Q2 2024 yet (1)

Institutions that held TScan Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding TCRX in Q1 2024 that haven't filed for Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
Credit Suisse AG	17,366	$137.9K